GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » Short Interest

Brainstorm Cell Therapeutics (STU:GHDN) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Brainstorm Cell Therapeutics Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Brainstorm Cell Therapeutics's Short Interest

For the Biotechnology subindustry, Brainstorm Cell Therapeutics's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Brainstorm Cell Therapeutics's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Brainstorm Cell Therapeutics's Short Interest distribution charts can be found below:

* The bar in red indicates where Brainstorm Cell Therapeutics's Short Interest falls into.


Brainstorm Cell Therapeutics (STU:GHDN) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Brainstorm Cell Therapeutics Inc (STU:GHDN) » Definitions » Short Interest
Comparable Companies
GNPX SEEL MYMD VBIV PHGE LEXX HEPA NRXS MBIO APM OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XKRX:068270 BNTX ALNY
Traded in Other Exchanges
BCLI:USA GHDN:Germany
Address
1325 Avenue of Americas, 28th Floor, New York, NY, USA, 10019
Website
https://www.brainstorm-cell.com
Brainstorm Cell Therapeutics Inc is a biotechnology company. The company is developing novel adult stem cell therapies for debilitating neurodegenerative disorders such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), and Parkinson's disease (PD). Brainstorm's NurOwn, its proprietary process for the propagation of Mesenchymal Stem Cells (MSC) and differentiation into neurotrophic factor-(NTF) secreting cells (MSC-NTF), and their transplantation at, or near, the site of damage, offers the hope of more effectively treating neurodegenerative diseases.

Brainstorm Cell Therapeutics (STU:GHDN) Headlines

No Headlines